Market: NMS |
Currency: USD
Address: Modi’in Technology Park
BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
📈 BioLineRx Ltd. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$26.00
-
Upside/Downside from Analyst Target:
738.71%
-
Broker Call:
4
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
50-100%
-
Net Income Growth Range (1Y):
50-100%
-
Revenue Growth Range (1Y):
0-10%
-
Upcoming Earnings Date:
2026-03-31
-
EPS Estimate:
-0.77
💰 Dividend History
| Year |
Annual Yield (%) |
Total Amount |
Current Yield (%) |
Ex Date |
Pay Date |
Particulars |
| 2025 |
- |
$0.025000 |
- |
2025-01-30 |
- |
Stock split |
|
Total Amount for 2025: $0.025000 |
| 2019 |
- |
$0.066667 |
- |
2019-07-15 |
- |
Stock split |
|
Total Amount for 2019: $0.066667 |
📅 Earnings & EPS History for BioLineRx Ltd.
| Date | Reported EPS |
|---|
| 2026-03-31 (estimated upcoming) | - |
| 2025-11-24 | - |
| 2025-08-14 | - |
| 2025-05-27 | - |
| 2024-11-25 | - |
| 2024-08-15 | - |
| 2024-05-28 | - |
| 2024-03-26 | -3.58 |
| 2023-11-20 | -12 |
| 2023-08-30 | -12 |
| 2023-05-24 | -6 |
| 2023-03-22 | - |
| 2022-11-15 | -6 |
| 2022-08-16 | -6 |
| 2022-05-11 | -0.4 |
| 2022-03-16 | - |
| 2021-11-18 | -6 |
| 2021-08-18 | -6 |
| 2021-05-26 | -0.8 |
| 2021-02-23 | -24 |
| 2020-11-23 | -12 |
| 2020-08-06 | -18 |
| 2020-05-20 | -24 |
| 2020-03-12 | -36 |
| 2019-11-11 | -1.2 |
📰 Related News & Research
No related articles found for "biolinerx ltd".
